Cancer is one of the world's leading causes of mortality. A number of conventional cytotoxic approaches for neoplastic diseases have been developed over the years. However, due to their limited effectiveness due to the heterogeneity of cancer cells, there is a constant search for therapeutic approaches with improved outcomes, such as immunotherapy, which utilizes and enhances the patient's immune system's normal capacity.Recently,Adoptive T cell immunotherapy has sparked a lot of interest in cancer treatment. Chimeric antigen T cell (CAR T) treatment has emerged in recent years as an advantageous therapy for treating cancer. CAR-T cell therapy is thought to be an effective treatment for relapsed or refractory tumors. Though the initially approved CAR-T anti-CD19 therapy produced impressive results, retrogressions, including high relapse rates and resistance, led to the need for detection of engineered cells more therapeutically efficient. Significant efficacy and persistence improvements in the design and manufacture of CAR-T cells have been achieved.